Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
前收盤價
US$21.79
+US$0.53 · +2.49%
盤後
US$21.79
US$0.00 · 0.00%
10月12日 下午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
日內區間
目前US$21.79
52週區間
目前US$21.79
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.41億 USD | 3.89億 USD | 3.54億 USD | 3.14億 USD | 2.99億 USD |
| 銷貨成本 | 1.71億 USD | 1.4億 USD | 1.25億 USD | 1.11億 USD | 1.01億 USD |
| 毛利 | 2.7億 USD | 2.49億 USD | 2.29億 USD | 2.03億 USD | 1.98億 USD |
| 研究與開發 | 3099.1萬 USD | 2845.2萬 USD | 2870.7萬 USD | 3887.9萬 USD | 3554.6萬 USD |
| 銷售、一般及管理費用 | 2.13億 USD | 1.92億 USD | 2.09億 USD | 1.57億 USD | 1.7億 USD |
| 營業費用 | 2.44億 USD | 2.1億 USD | 2.23億 USD | 1.96億 USD | 1.89億 USD |
| 利息收入 | 76.3萬 USD | 146.7萬 USD | 107.7萬 USD | 14.7萬 USD | 7.9萬 USD |
| 利息支出 | 2658.2萬 USD | 3427.7萬 USD | 2529.9萬 USD | 1822.4萬 USD | 1688.7萬 USD |
| 折舊和攤銷 | 2245.8萬 USD | 2420.5萬 USD | 2307.6萬 USD | 2244.2萬 USD | 2397.7萬 USD |
| 營業利益 | 2674.5萬 USD | 3887.4萬 USD | 574.2萬 USD | 620.1萬 USD | 811.7萬 USD |
| 淨利 | 976.8萬 USD | −1335.9萬 USD | −3069萬 USD | −1919.2萬 USD | −1483.4萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$42.50
上漲空間 95.04%年度分割調整後的每股現金分配。
US$0.12
2015年(完整年度)+11.6% 自從 2013
US$0.1075
2,013
US$0.1175
2,014
US$0.12
2,015
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2015年12月9日 | US$0.03Quarterly | 2015年12月11日 | 2015年12月18日 |
股息 | 2015年9月9日 | US$0.03Quarterly | 2015年9月11日 | 2015年9月18日 |
股息 | 2015年6月10日 | US$0.03Quarterly | 2015年6月12日 | 2015年6月19日 |
股息 | 2015年3月11日 | US$0.03Quarterly | 2015年3月13日 | 2015年3月20日 |
股息 | 2014年12月10日 | US$0.03Quarterly | 2014年12月12日 | 2014年12月19日 |
股息 | 2014年9月10日 | US$0.03Quarterly | 2014年9月12日 | 2014年9月19日 |
除息 2015年12月9日
US$0.03
Quarterly
2015年12月11日登記 · 支付日 2015年12月18日
除息 2015年9月9日
US$0.03
Quarterly
2015年9月11日登記 · 支付日 2015年9月18日
除息 2015年6月10日
US$0.03
Quarterly
2015年6月12日登記 · 支付日 2015年6月19日
除息 2015年3月11日
US$0.03
Quarterly
2015年3月13日登記 · 支付日 2015年3月20日
除息 2014年12月10日
US$0.03
Quarterly
2014年12月12日登記 · 支付日 2014年12月19日
除息 2014年9月10日
US$0.03
Quarterly
2014年9月12日登記 · 支付日 2014年9月19日
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3949.55萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2531.49萬0.03%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1340.47萬0.01%954億 USD0.05%US$233.52-0.63%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM950.54萬0.06%157.12億 USD0.03%US$53.42-0.06%
iShares Russell 2000 Growth ETFIWO897.57萬0.06%139.17億 USD0.24%US$353.71-0.86%
Dimensional - US Small Cap ETFDFAS739.51萬0.02%338.69億 USD0.31%US$78.17-0.23%
Vanguard Russell 2000 ETFVTWO709.13萬0.04%180億 USD0.06%US$112.27-0.35%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG604.42萬0.13%48.09億 USD0.15%US$108.33-0.22%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
iShares Russell 2000 Growth ETFIWO
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
State Street SPDR S&P 600 Small Cap Growth ETFSLYGAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。